Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1998

View Archived Issues

L-Glutamine therapy beneficial for sickle cell anemia

TR1, new member of the TNFR superfamily and target for treating metabolic bone diseases

PKA I may be a valid target for immunomodulation in the HIV-infected patient

Bromocriptine reduces prolactin levels in patients with androgen-independent prostate cancer

Potent anti-HSV-1 activity demonstrated with BILD-1633-SE in vivo

Matrix granted Japanese patent; U.S. patent reissued

Anika: Q2 1998 highlights

Diacrin: Q2 1998 highlights

Salix: Q2 1998 highlights

Results support development of beta-L-Fd4C as an expanded-spectrum anti-HBV drug

Patent issued for Techniclone's Vascular Targeting Agent technology

Carotid artery intimal thickening prevented by TAS-301

New COX-2 inhibitors in early development at American Home

P&U discloses new distamycin derivatives with antitumor/antiviral efficacy

Two new series of PDE4 inhibitors reported by Byk Gulden

Otsuka adds new antidiabetic candidates to R&D pipeline

Insulin-sensitizing guanidine compounds discovered by Yamanouchi

Nonamine compounds inhibit monoamine transporters, contrary to prevailing beliefs

SynPhar's HLE inhibitors show unique potential in preventing lung injury

Ligand-Seragen merger process now completed

First filing for Novo Nordisk's fast-acting insulin analogue

The Medicines Company acquires clinical-stage antimigraine drug for development

SB-237376, a new antiarrhythmic agent with a dual mechanism of action and enhanced safety

Kissei studies beta-adrenergic drug for use in patients with urolithiasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.